Have you secured your place at the Protein Degradation & Targeting Undruggables Congress Europe yet? Join companies in attendance, such as: Amphista Therapeutics Limited, AstraZeneca, Bayer, Biognosys, Boehringer Ingelheim, C4 Therapeutics, Inc., Captor Therapeutics SA, Collaborative Drug Discovery - CDD VAULT, Celeris Therapeutics, Cellestia Biotech, Concept Life Sciences, Cullgen Inc., Dunad Therapeutics, Enamine PL, ETH Zürich, Fida Biosystems, FIMECS, Inc., Firefly Biologics, Flagship Pioneering, Genentech and GSK The final EARLY BIRD discount ends this Friday! (August 25) Register now and save up to €300: https://lnkd.in/efyfd4ZA #molecularbiology #protac #oncology #proteindegradation
About us
Dedicated to supporting the development of novel pharmaceutical modalities – RNA therapeutics, protein degraders, transcription inhibitors – these conferences provide exclusive insight to pioneering drug development programs, the most influential and important stakeholders, and invaluable horizon scanning for researchers. Focused agendas will provide an in-depth review of industry drug pipelines, pinpoint structural biology and computational advancements, and inform R&D teams on re-engineering strategies for experimental nucleic-acid, biologic and small-molecule compounds. In the changing landscape of undruggability, join this biopharma-led series to remain at the forefront of the next generation of novel therapeutic entities.
- Industry
- Research Services
- Company size
- 11-50 employees
- Headquarters
- Basel
- Type
- Privately Held
- Founded
- 2019
- Specialties
- undruggables, protein degradation, Targeting RNA, drug discovery, protein misfolding, and neurodegenerative disease